Peroxisome Proliferator-Activated Receptor-Gamma Agonists for Alzheimer’s Disease and Amnestic Mild Cognitive Impairment: A Systematic Review and Meta-Analysis

Drugs and Aging

Volumn 32, Issue 1, 2015, Pages 57-65

  Liu, Jia ^a   Wang, Lu ning ^b   Jia, Jian ping ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE SUBSCALE; CLINICAL DEMENTIA RATING; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HUMAN; META ANALYSIS; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; PERIPHERAL EDEMA; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; WECHSLER MEMORY SCALE; AGONISTS;

ALZHEIMER DISEASE; HUMANS; HYPOGLYCEMIC AGENTS; MILD COGNITIVE IMPAIRMENT; PPAR GAMMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLIDINEDIONES;

EID: 84925496945     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-014-0228-7     Document Type: Review

References (33)

1. Liu J, Wang LN, Tan JP. Dementia in China: current status. Neurology. 2013;81:1077–8.
2. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366:2112–7.
3. Price JL, McKeel DW Jr, Buckles VD, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009;30:1026–36.
4. van Exel E, Eikelenboom P, Comijs H, et al. Vascular factors and markers of inflammation in offspring with a parental history of late-onset Alzheimer disease. Arch Gen Psychiatry. 2009;66:1263–70.
5. Schapira AH. Mitochondrial diseases. Lancet. 2012;379:1825–34.
6. Roriz-Filho JS, Sá-Roriz TM, Rosset I, et al. (Pre)diabetes, brain aging, and cognition. Biochim Biophys Acta. 2009;1792:432–43.
7. Xu WL, von Strauss E, Qiu CX, Winblad B, Fratiglioni L. Uncontrolled diabetes increases the risk of Alzheimer’s disease: a population-based cohort study. Diabetologia. 2009;52:1031–9.
8. Pilcher H. Alzheimer’s disease could be “type 3 diabetes”. Lancet Neurol. 2006;5:388–9.
9. Reger MA, Watson GS, Green PS, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology. 2008;70:440–8.
10. Craft S, Asthana S, Newcomer JW, et al. Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch Gen Psychiatry. 1999;56:1135–40.
11. Hölscher C. The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer’s disease. Alzheimers Dement. 2014;10:S47–54.
12. van Bilsen M, van Nieuwenhoven FA. PPARs as therapeutic targets in cardiovascular disease. Expert Opin Ther Targets. 2010;14:1029–45.
13. Jiang Q, Heneka M, Landreth GE. The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer’s disease: therapeutic implications. CNS Drugs. 2008;22:1–14.
14. Shibata N, Motoi Y, Tomiyama H, et al. Lack of genetic associations of PPAR-gamma and PGC-1alpha with Alzheimer’s disease and Parkinson’s disease with dementia. Dement Geriatr Cogn Disord Extra. 2013;3:161–7.
15. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011. Available from: http://www.cochrane-handbook.org. Accessed 22 June 2014.
16. Geldmacher DS, Fritsch T, McClendon MJ, Landreth G. A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch Neurol. 2011;68:45–50.
17. Hanyu H, Sato T, Kiuchi A, Sakurai H, Iwamoto T. Pioglitazone improved cognition in a pilot study on patients with Alzheimer’s disease and mild cognitive impairment with diabetes mellitus. J Am Geriatr Soc. 2009;57:177–9.
18. Hanyu H, Sato T, Sakurai H, Iwamoto T. The role of tumor necrosis factor-alpha in cognitive improvement after peroxisome proliferator-activator receptor gamma agonist pioglitazone treatment in Alzheimer’s disease. J Am Geriatr Soc. 2010;58:1000–1.
19. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging. 2011;32:1626–33.
20. Gold M, Alderton C, Zvartau-Hind M, et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer’s disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord. 2010;30:131–46.
21. Harrington C, Sawchak S, Chiang C, et al. Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer’s disease: two phase 3 studies. Curr Alzheimer Res. 2011;8:592–606.
22. Risner ME, Saunders AM, Altman JF, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease. Pharmacogenomics J. 2006;6:246–54.
23. Tzimopoulou S, Cunningham VJ, Nichols TE, et al. A multi-center randomized proof-of-concept clinical trial applying [18F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer’s disease. J Alzheimers Dis. 2010;22:1241–56.
24. Watson GS, Cholerton BA, Reger MA, et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry. 2005;13:950–8.
25. Takeda Study Registration. About the TOMMORROW study (NCT01931566). Tommorrowstudy.com. 2013. Available from: http://www.tommorrowstudy.com/TommorrowStudy.aspx#.VEem_HDexN0. Accessed 22 June 2014.
26. Liu J, Wang LN. Caregivers of patients with dementia in Chinese mainland: a retrospective analysis. Am J Alzheimers Dis Other Demen. 2013;28:679–81.
27. Liu J, Wang LN, Tan JP, et al. Burden, anxiety and depression in caregivers of veterans with dementia in Beijing. Arch Gerontol Geriatr. 2012;55:560–3.
28. Adelman RD, Tmanova LL, Delgado D, Dion S, Lachs MS. Caregiver burden: a clinical review. JAMA. 2014;311:1052–60.
29. Moon JH, Kim HJ, Yang AH, et al. The effect of rosiglitazone on LRP1 expression and amyloid β uptake in human brain microvascular endothelial cells: a possible role of a low-dose thiazolidinedione for dementia treatment. Int J Neuropsychopharmacol. 2012;15:135–42.
30. Miller BW, Willett KC, Desilets AR. Rosiglitazone and pioglitazone for the treatment of Alzheimer’s disease. Ann Pharmacother. 2011;45:1416–24.
31. Liu J, Wang LN. Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack. Cochrane Database Syst Rev. 2014;(1):CD010693.
32. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010;170:1191–201.
33. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2007;298:1180–8.